Sublingual immunotherapy (SLIT) has been used in human medicine with good success for allergic rhinitis and asthma. More recently beneficial effects have been reported for atopic dermatitis. An advantage of SLIT is ease of administration and tolerability. Limited studies exist in veterinary medicine. The purpose of the present study was to evaluate safety and efficacy of SLIT in an experimental model for canine atopic dermatitis.
1. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. The Journal of Allergy and Clinical Immunology, Volume 120, Issue6, Pages 1338 – 1345, December 2007, Alain Didier, MD, Hans-Jörgen Malling, MD, Margitta Worm, MD, Friedrich Horak, MD, Siegfried Jäger, PhD, Armelle Montagut, PhD, Claude André, MD, Olivier de Beaumont, MD, Michel Melac, MD.
2. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergol Immonopathol (Madr). 2000 Mar-Apr;28(2):54-62. Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G, Coradduzza G, Parmiani S.
3. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. The Journal of Allergy and Clinical Immunology, Volume 120, Issue 1, Pages 164-170, July 2007. Giovanni B. Pajno, MD, Lucia Caminiti, MD, Daniela Vita, MD, Giovanni Barberio, MD, Giuseppina Salzano, MD, Fortunato Lombardo, MD, Giorgio Walter Canonica, MD, Giovanni Passalacqua, MD.
Download a PDF of the SLIT Study